We claim:

1. A compound of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein:

R^1 is H, alkyl, haloC_1-C_6 alkyl, cycloalkyl, cycloalkylNH-, arylalkyl, heterocycloalkyl, heteroaryl, $N(R^2)_2$, or NR^2aryl, unsubstituted aryl or aryl substituted with one to three X;

R^2 is the same or different in each occurrence and is independently selected from H or C_1-C_6 alkyl;

R^3 is H, C_1-C_6 alkyl, Cl, F, CF_3, OCF_2H, OCF_3, OH or C_1-C_6 alkoxy;

R^4 is H, C_1-C_6 alkyl, C_1-C_6 alkoxy, cycloalkyl, alkenyl, aryl, benzyl, heteroaryl, heterocycloalkyl, arylNH-, heteroarylNH-, cycloalkylNH-, $N(R^2)_2$, or NR^2aryl, said alkyl, alkoxy, cycloalkyl, alkenyl, phenyl or heteroaryl optionally substituted with one to three X;

R^5 is H or C_1-C_6 alkyl;

R^6 is H or C_1-C_6 alkyl; or

R^5 and R^6 taken together with the carbon atom form a carbonyl group;

L^1 is C_1-C_6 alkylene, C_2-C_6alkenylene, $C(R^2)_2$,  , -$CHOR^2$-, NOR^5-, -SO_2-, -SO-, -S-, -O-, -NR^2-, -$C(O)NR^2$-, -$NR^2C(O)$-, -$CHCF_3$- or -CF_2-;

L^2 is a covalent bond, C_1-C_6 alkylene, -$C(R^2)_2$-,  , -$CHOR^2$-, -$C(R^2)OH$, NOR^5-, -SO_2-, -NR^2SO_2-, -SO-, -S-, -O-, -SO_2NR^2-, -$N(R^2)$-, -$C(O)NR^2$- or -$NR^2C(O)$-;

X is the same or different, and is independently selected from H, halogen, CF_3, CN, OCF_2H, OCF_2CF_3, OCF_3, OR^2, C_1-C_6 alkyl, cycloalkyl, cycloalkoxy, C_1-C_6 alkoxy, alkoxyC_1-C_6 alkoxy, O-cycloalkyl, cycloalkylamino, cycloalkylalkoxy, heteroalkyl, -OSO_2R^2, -$COOR^2$, -$CON(R^2)_2$, NHR^2, arylNH-, $N(R^2)_2$, or NR^2 aryl;

Y is a covalent bond, -CH_2-, -SO_2-, or  ;

Z is a covalent bond, -CH_2-, -SO_2- or  ; or

Y, R^1, Z and R^2 can be taken together with the nitrogen atom to form a heterocycloalkyl; with the proviso that if Y is a covalent bond, R^1 cannot form a N-N bond with the nitrogen atom; and

n is an integer of 0 to 4.

2. A compound according to claim 1 wherein

L^1 is -SO_2-, -CH_2-, -$CHCH_3$-,  , -C=NOR^2-, -$C(CH_3)_2$-, -CHOH-, -O-, -S- or -S=O;

L^2 is -SO_2-,  , -CH_2-, -$CH(CH_3)$-,-$C(CH_3)_2$-,  , -NH-, -O-, -$NHSO_2$-, -NHC(O)- or  ;

R^1 is H, -CH_3NH_2, -CH_2CF_3, -NHC_3H_7, -NHC_2H_6, -NHC_4H_9, C_1-C_6 alkyl, -CF_3, -$CH(CH_3)_2$, thiophenyl, morpholinyl, cyclopropanyl, benzyl, naphthyl, $C(CH_3)_3$, NHphenyl, 3,5-difluorophenyl, phenyl, N-cyclopentyl or $N(CH_3)_2$;

R^2 is H or CH_3;

R^4 is furanyl, pyridyl, pyrimidyl, thiophenyl, quinolyl, t-butoxy, alkoxyl, cyclohexyl, phenyl, tolyl, C_3H_7, dimethylpyrimdyl, trifluoromethoxyphenyl, morpholinylphenyl or CH_3; with the proviso that when R^4 is t-butoxy, L^2 must be

 , $-CH_2-$, $-CHCH_3-$, $-C(CH_3)_2-$ or , all of the above optionally substituted with one to three substituents, which are the same or different and are independently selected from X;

R^5 and R^6 are independently H or CH_3;

X is H, Cl, CF_3, OCH_3, OCF_3, OCF_2H, CH_3 or C_1-C_6 cycloalkyl;

Y is $-SO_2-$ or  ;

Z is a covalent bond; or

R^1, Y, R^2 and Z taken together with the nitrogen atom form a morpholinyl group.

3. The compound according to claim 2 wherein

L^1 is $-SO_2-$ or $-CH_2-$;

L^2 is $-SO_2-$;

R^1 is CH_3 or CF_3; and

R^4 is phenyl, pyrimidyl or pyridyl, each of said phenyl, pyrimidyl or pyridyl optionally substituted with one to three substitutents which are the same or different, and are independently selected from the group consisting of C_1-C_6 alkyl, C_1-C_6 alkoxy, OH, CF_3 and halogen.

4. The compound according to claim 3 wherein the phenyl in R^4 is substituted with OCH_3 or halogen.

5. The compound according to claim 4 wherein the halogen is selected from fluorine and chlorine.

6. The compound according to Claim 1 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug;

wherein X and R^4 are as shown in the table below:

	X	R^4
	OCH_3	
	OCH_3	
	OCF_2H	
	OCH_3	
	CH_3	
	OCH_3	
	OCF_3	
	Cl	

	X	R^4
	Cl	
	OCH_3	
	CH_3	
	Cl	
	OCH_3	
	OCH_3	
	OCH_3	C_3H_7
	CF_3	
	CF_3	
	CF_3	
	CF_3	
	Cl	

	X	R^4
	Cl	
	Cl	
	Cl	
	Cl	
	Cl	
	Cl	C_3H_7
	OCF_3	
	OCF_3	
	OCF_3	
	OCH_3	
	OCH_3	
	CH_3	

	X	R^4
	Cl	
	Cl	
	OH	
	OH	
	OCF_2H	
	H	
	H	
	H	
	H	
	H	

7. The compound according to Claim 1 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug;

wherein X and R^4 are as shown in the table below:

	X	R^4
	CF_3	
	Cl	
	Cl	
	CF_3	
	CF_3	
	CF_3	

	Cl	
	Cl	
	Cl	
	Cl	
	OCF_3	
	OCH_3	
	CH_3	
	CH_3	
	H	
	H	
	Cl	

	CF_3	
	Cl	
	OCH_3	
	OH	
	$OCH(CH_3)_2$	
		

8. The compound according to Claim 1 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug;

wherein X, R^1 and R^4 are as shown in the table below:

	X	R^1	R^4
	OCH_3	CH_3	
	OCF_2H	CH_3	
	CH_3	CH_3	
	Cl	CH_3	
	CF_3	CF_3	
	Cl	CF_3	
	CF_3	CH_3	
	Cl	$N(CH_3)_2$	
	OCF_3	CH_3	
	OCF_3	CF_3	
	CH_3	CF_3	
	Cl	CH_3	

	X	R^1	R^4
	H	CH_3	
	H	CF_3	
	Cl	CF_3	
	CF_3	CF_3	
		CF_3	
		CF_3	
		CF_3	
	CN	CF_3	
	NH_2	CF_3	
		CF_3	
	Cl	CF_3	
	Cl	CF_3	

	X	R^1	R^4
		CF_3	
	CN	CF_3	
	$-CONH_2$	CF_3	
	$-OCH_3$	CF_3	
	-OH	CF_3	
		CF_3	
		CF_3	
		CF_3	
		CF_3	
		CF_3	
	OCH_3	CF_3	
		CH_3	

9. The compound according to Claim 1 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is OCH_3 and R^1 is CH_3.

10. The compound according to Claim 1 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is OCF_2H and R^1 is CH_3.

11. The compound according to Claim 1 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is CH_3 and R^1 is CH_3.

12. The compound according to Claim 1 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is Cl and R^1 is CH_3.

13. The compound according to Claim 1 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is CF_3 and R^1 is CF_3.

14. The compound according to Claim 1 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is Cl and R^1 is CF_3.

15. The compound according to Claim 1 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is CF_3 and R^1 is CH_3.

16. The compound according to Claim 1 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is Cl and R^1 is $N(CH_3)_2$.

17. The compound according to Claim 1 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is OCF_3 and R^1 is CH_3.

18. The compound according to Claim 1 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is OCF_3 and R^1 is CF_3.

19. The compound according to Claim 1 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is CH_3 and R^1 is CF_3.

20. The compound according to Claim 1 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is cyclopropyl and R^1 is CF_3.

21. The compound according to Claim 1 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is H and R^1 is CH_3.

22. The compound according to Claim 1 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is H and R^1 is CF_3.

23. The compound according to Claim 1 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is Cl and R^1 is CF_3.

24. The compound according to Claim 1 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is CF_3 and R^1 is CF_3.

25. The compound according to Claim 1 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is cyclopropyl and R^1 is CF_3.

26. The compound according to Claim 1 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is Cl and R^1 is CF_3.

27. The compound according to Claim 1 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is cyclopropyl and R^1 is CH_3.

28. The compound according to Claim 1 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is cyclopropyl and R^1 is CF_3.

29. The compound according to Claim 1 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is cyclopropyl and R^1 is CH_3.

30. A pharmaceutical composition comprising an effective amount of a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, according to claim 1 and a pharmaceutically acceptable carrier.

31. A pharmaceutical composition comprising an effective amount of a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, according to claim 7 and a pharmaceutically acceptable carrier.

32. A method of stimulating cannabinoid CB_2 receptors in a mammal comprising administering to a mammal having CB_2 receptors an effective CB_2 receptor stimulating amount of a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, according to Claim 1.

33. A method of treating cancer, inflammatory diseases, immunomodulatory diseases, or respiratory diseases comprising administering to a mammal in need of such treatment an effective amount of a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, according to claim 1.

34. A method of treating cutaneous T cell lymphoma, rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, glaucoma, diabetes, sepsis, shock, sarcoidosis, idiopathic pulmonary fibrosis, bronchopulmonary dysplasia, retinal disease, scleroderma, osteoporosis, renal ischemia, myocardial infarction, cerebral stroke, cerebral ischemia, nephritis, hepatitis, glomerulonephritis, cryptogenic fibrosing alveolitis, psoriasis, atopic dermatitis, vasculitis, allergy, seasonal allergic rhinitis, Crohn's disease, inflammatory bowel disease, reversible airway obstruction, adult respiratory distress syndrome, asthma, chronic obstructive pulmonary disease (COPD), bronchitis, colitis, coronary artery disease, melanoma, transplant rejection, graft versus host disease, Hashimoto's thyroiditis, Graves disease, myasthenia gravis or Goodpasture's syndrome comprising administering to a mammal in need of such treatment an effective amount of a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, according to claim 1.

35. The method of claim 32 wherein the condition or disease treated is selected from rheumatoid arthritis, multiple sclerosis, seasonal allergic rhinitis and chronic obstructive pulmonary disease.

36. A pharmaceutical composition made by combining the compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the

compound or of said prodrug, of Claim 1 and a pharmaceutically acceptable carrier therefor.

37. A process for making a pharmaceutical composition comprising combining a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, of Claim 1 and a pharmaceutically acceptable carrier.

38. A method of treating rheumatoid arthritis which comprises co-administration of a compound selected from the class consisting of a COX-2 inhibitor, a COX-1 inhibitor, an immunosuppressive, a steroid, an anti-TNF-α compound or other classes of compounds indicated for the treatment of rheumatoid arthritis and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, as defined in Claim 1.

39. A method of treating rheumatoid arthritis which comprises co-administration of a compound selected from the class consisting of a COX-2 inhibitor, a COX-1 inhibitor, an immunosuppressive, a steroid, an anti-TNF-α compound, a PDE IV inhibitor or other classes of compounds indicated for the treatment of rheumatoid arthritis and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, as defined in Claim 7.

40. The method of Claim 38 wherein the COX-2 inhibitor is Celebrex or Vioxx, the COX-1 inhibitor is Feldene, the immunosuppressive is methotrexate, leflunimide, sulfasalazine or cyclosporin, the steroid is β-methasone and the anti-TNF-α compound is Enbrel or Remicade.

41. The method of Claim 39 wherein the COX-2 inhibitor is Celebrex or Vioxx, the COX-1 inhibitor is Feldene, the immunosuppressive is methotrexate, leflunimide, sulfasalazine or cyclosporin, the steroid is β-methasone and the anti-TNF-α compound is Enbrel or Remicade.

42. A composition for treating rheumatoid arthritis which comprises a compound selected from the class consisting of a COX-2 inhibitor, a COX-1 inhibitor, an immunosuppressive, a steroid, an anti-TNF-α compound or other classes of compounds indicated for the treatment of rheumatoid arthritis and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, as defined in Claim 1.

43. A composition for treating rheumatoid arthritis which comprises a compound selected from the class consisting of a COX-2 inhibitor, a COX-1 inhibitor, an immunosuppressive, a steroid, an anti-TNF-α compound or other classes of compounds indicated for the treatment of rheumatoid arthritis and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, as defined in Claim 7.

44. The composition of Claim 42 wherein the COX-2 inhibitor is Celebrex or Vioxx, the COX-1 inhibitor is Feldene, the immunosuppressive is methotrexate, leflunimide, sulfasalazine or cyclosporin, the steroid is β-methasone and the anti-TNF-α compound is Enbrel or Remicade.

45. The composition of Claim 43 wherein the COX-2 inhibitor is Celebrex or Vioxx, the COX-1 inhibitor is Feldene, the immunosuppressive is methotrexate, leflunimide, sulfasalazine or cyclosporin, the steroid is β-methasone and the anti-TNF-α compound is Enbrel or Remicade.

46. A method of treating multiple sclerosis which comprises co-administration of a compound selected from Avonex, Betaseron, Copaxone or other compounds indicated for the treatment of multiple sclerosis and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, as defined in Claim 1.

47. A method of treating multiple sclerosis which comprises co-administration of a compound selected from Avonex, Betaseron, Copaxone or other

compounds indicated for the treatment of multiple sclerosis and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, as defined in Claim 7.

48. A composition for treating multiple sclerosis which comprises a compound selected from Avonex, Betaseron, Copaxone or other compounds indicated for the treatment of multiple sclerosis and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, as defined in Claim 1.

49. A composition for treating multiple sclerosis which comprises a compound selected from Avonex, Betaseron, Copaxone or other compounds indicated for the treatment of multiple sclerosis and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, as defined in Claim 7.

50. A method of treating psoriasis which comprises co-administration of a compound selected from the class consisting of an immunosuppressive, a steroid, an anti-TNF-α compound or other classes of compounds indicated for the treatment of psoriasis and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, as defined in Claim 1.

51. A method of treating psoriasis which comprises co-administration of a compound selected from the class consisting of an immunosuppressive, a steroid, an anti-TNF-α compound or other classes of compounds indicated for the treatment of psoriasis and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, as defined in Claim 7.

52. The method of Claim 50 wherein the immunosuppressive is methotrexate, leflunimide, sulfasalazine or cyclosporin, the steroid is β-methasone and the anti-TNF-α compound is Enbrel or Remicade.

53. The method of Claim 51 wherein the immunosuppressive is methotrexate, leflunimide, sulfasalazine or cyclosporin, the steroid is β-methasone and the anti-TNF-α compound is Enbrel or Remicade.

54. A composition for treating psoriasis which comprises a compound selected from the class consisting of an immunosuppressive, a steroid, an anti-TNF-α compound or other classes of compounds indicated for the treatment of psoriasis and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, as defined in Claim 1.

55. A composition for treating psoriasis which comprises a compound selected from the class consisting of an immunosuppressive, a steroid, an anti-TNF-α compound or other classes of compounds indicated for the treatment of psoriasis and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, as defined in Claim 7.

56. The composition of Claim 54 wherein the immunosuppressive is methotrexate, leflunimide, sulfasalazine or cyclosporin, the steroid is β-methasone and the anti-TNF-α compound is Enbrel or Remicade.

57. The composition of Claim 55 wherein the immunosuppressive is methotrexate, leflunimide, sulfasalazine or cyclosporin, the steroid is β-methasone and the anti-TNF-α compound is Enbrel or Remicade.